Clinical Trials Browser

Phase 2 × Electrochemotherapy × Dermatologic × Clear all

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Phase 2 Withdrawn

Melanoma